Our portfolio

To date, CEPI has established multiple partnership agreements, reflecting a potential investment of up to $456 million. Through these collaborations, we're supporting the development of a wide range of vaccine candidates and platform technologies.

We also have number of additional partnerships under negotiation. These partnership agreements represent the start of CEPI’s product development portfolio.

PRODUCT DEVELOPERS
  • All
  • Colorado State University
  • CureVac
  • IDT Biologika
  • Imperial College London
  • Inovio Pharmaceuticals
  • International AIDS Vaccine Initiative
  • Janssen Vaccines & University of Oxford
  • Profectus Biosciences, Emergent Biosolutions & PATH
  • Public Health Vaccines
  • Themis Bioscience
  • University of Queensland
  • University of Tokyo
  • Valneva SE
  • Wageningen Bioveterinary Research
DISEASE
  • All
  • Chikungunya
  • Lassa virus
  • Marburg virus
  • MERS coronavirus
  • Nipah virus
  • Rift Valley Fever
VACCINE TYPE
  • All
  • Live attenuated vaccine
  • Nucleic acid
  • Recombinant protein
  • Recombinant viral vector
PHASE
  • All
  • Phase 1
  • Phase 2
  • Phase 3
  • Preclinical
{{ mob.finishButton }}
Filter by product developers:
Filter by disease:
Filter by vaccine type:
Filter by phase:

{{ dev['funding_title'] }}

{{ dev['funding'] }}

{{ d['disease'] }}
{{ d['vaccine_type'] }}
{{ d['trial_title'] }}
{{ d['trial'] }}
{{ d['phase'] }}
?
?

{{ d['description'] }}

N/A
No result